MARLBOROUGH, Mass.,
Oct. 4, 2017 /PRNewswire/
-- Hologic, Inc. (NASDAQ: HOLX) announced today that it has
launched, subject to market and other conditions, a private
offering of $350 million aggregate
principal amount of senior notes due 2025. Hologic intends to
use the proceeds of the offering and available cash, including
funds from its new five-year secured credit agreement, to retire
the Company's remaining convertible notes, including through
repurchases or redemptions, when they become callable in December
of 2017 and March of 2018.
The 2025 notes will not be registered under the Securities Act
of 1933, as amended, or any state securities laws. Unless so
registered, the securities may not be offered or sold in
the United States except pursuant
to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and applicable
state securities law. The 2025 notes are being offered only
to qualified institutional buyers in reliance on Rule 144A under
the Securities Act, and outside the
United States in accordance with Regulation S under the
Securities Act.
This press release is neither an offer to sell nor a
solicitation of an offer to buy any of these securities, nor shall
there be any offer, solicitation or sale of these securities in any
jurisdiction where the offer, solicitation or sale is not
permitted.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information on
Hologic, visit www.hologic.com.
Hologic, The Science of Sure, and associated logos are
trademarks and/or registered trademarks of Hologic, Inc. and/or its
subsidiaries in the United States
and/or other countries.
Forward-Looking Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions.
Such statements include, without limitation, the Company's
intention to issue the 2025 notes and the use of proceeds of the
offering, including the Company's plans to retire its remaining
convertible notes. These forward-looking statements are
subject to known and unknown risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. The offering may also be
adversely affected by prevailing credit markets, which have been
subject to significant volatility, or adverse changes to Hologic's
business or prospects. Hologic cannot assure it will complete
the issuance of the 2025 notes on favorable terms, if at all.
In addition, Hologic's election to redeem or repurchase the
convertible notes will be at its sole discretion, based upon market
and business conditions at the time of such determination.
The risks included above are not exhaustive. Other factors
that could adversely affect the Company's business and prospects
are described in the filings made by Hologic with the SEC.
Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any
change in events, conditions or circumstances on which any such
statements are based.
Contact
Michael
Watts
Vice President, Investor Relations and
Corporate Communications
(858) 410-8588
View original
content:http://www.prnewswire.com/news-releases/hologic-announces-offering-of-350-million-of-senior-notes-due-2025-300530802.html
SOURCE Hologic, Inc.